Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RECARBRIO | Merck & Co | N-212819 RX | 2019-07-16 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
recarbrio | New Drug Application | 2024-10-28 |
Expiration | Code | ||
---|---|---|---|
CILASTATIN SODIUM / IMIPENEM / RELEBACTAM, RECARBRIO, MSD MERCK CO | |||
2029-07-16 | GAIN | ||
2024-07-16 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Cilastatin Sodium / Imipenem / Relebactam, Recarbrio, Msd Merck Co | |||
8487093 | 2029-11-19 | DS, DP | U-2586, U-2587, U-2840 |
Code | Description |
---|---|
J0742 | Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg |
Drug common name | Relebactam |
INN | relebactam |
Description | Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor, it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio).
... More |
Classification | Small molecule |
Drug class | beta-lactamase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O.O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O |
PDB | — |
CAS-ID | 1174018-99-5 |
RxCUI | — |
ChEMBL ID | CHEMBL3301605 |
ChEBI ID | — |
PubChem CID | 44129647 |
DrugBank | DB12377 |
UNII ID | 1OQF7TT3PF (ChemIDplus, GSRS) |